NCT01739127View on ClinicalTrials.gov

Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI

CompletedOBSERVATIONAL
Enrollment

83

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Psychotic DisordersBipolar DisorderMetabolic Syndrome X
Interventions
DRUG

Aripiprazole

To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).

DRUG

Risperidone/Quetiapine

To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).

Trial Locations (1)

V5Z 4H4

BC Mental Health & Addictions Research Institute, Vancouver

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of British Columbia

OTHER

NCT01739127 - Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI | Biotech Hunter | Biotech Hunter